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Correlation Between Pre-Collection CD34 Blood
Concentrations and CD34 Collection Yield in Difﬁcult-to-
Mobilize Patients Given Plerixafor: A Retrospective Single
Center Study
Odelia Amit, Ron Ram, Rinat Eshel, Esti Rom, Aviva Pinchasov,
Irit Avivi. Bone Marrow Transplant Unit, Tel Aviv Medical Center
and Sackler Faculty of Medicine, Tel Aviv, Israel
Background: Pre-collection CD34 blood concentrations have
been shown to predict collection yield in patients mobilized
with G-CSF +/- chemotherapy. We aimed to study this asso-
ciation in a cohort of difﬁcult to mobilize patients who were
given Plerixafor in addition to standard mobilization regimen.
Methods: We performed a retrospective cohort study of all
cases (n¼58) of patients (n¼31) who were difﬁcult to
mobilize and given Plerixafor prior to collection between the
years 2009 and 2014. Correlation between pre-collection
CD34 and collection yield was measured using the Pearson’s
chi squared test and goodness of ﬁt with a linear regression.
Two-sided p values are presented.
Results: Patients’ median age was 45 (range, 5e71) years,
54% were female. Baseline disease was lymphoma (74%),
Multiple Myeloma (10%) and solid malignancies (16%). Thirty
two percent of patients had >2 previous therapies, 36% prior
radiation therapy and 42% chemorefractory disease. Seventy
six percent of cases were collected at steady state (G-CSF +
Plerixafor) and 24% collected post chemotherapy and G-CSF.
There was a signiﬁcant correlation between pre-collec-
tion CD34 blood concentrations and CD34 collection yield
(r¼.93 (95% CI.88-.96, p<.001) with r2 in logistic regression of
.86, p<.001. Receiver operating curve to predict sufﬁcient
CD34 collection (Figure 1) showed at a pre-collection CD34
blood concentrations of >9.5 cells/ul sensitivity was 88%
(95% CI68.8-97.4) and speciﬁcity was 67.7% (95% CI48.6-
83.3). For CD34 blood concentrations >19 cells/ul sensitivity
was 84% (95% CI63.9-95.5) and speciﬁcity was 100% (95% CI
88.8-100.0). For CD34 blood concentrations of >9.5 cells/ul
and >19 cells/ul the negative predictive and positive pre-
dictive values were 69%, 92% and 100%, 88%, respectively.
Conclusion: Pre-collection CD34 blood concentration in
difﬁcult to mobilize patients given Plerixafor is a strong
predictor of successful collection with the value of >19 cells/
ul associated with 84% sensitivity and 100% speciﬁcity.Figure 1.181
Effectively Targeting Burkitt Lymphoma By Anti-CD20
Chimeric Antigen Receptor (CAR) Modiﬁed Expanded
Natural Killer Cells Combined with a Histone Deacetylase
Inhibitor, Romidepsin in Vitro and In Humanized
NSG Mice
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Valhalla, NY; 5Medicine, New York Medical College, Valhalla, NYBackground: The outcome for patients with Burkitt lym-
phoma (BL) has improved signiﬁcantly but for patients who
relapse, the prognosis is dismal due to chemo-radiotherapy
resistance (Cairo et al, JCO, 2012). Our group has successfully
engineered expanded peripheral blood Natural Killer cells
(exPBNK) with an anti-CD20 chimeric antigen receptor (CAR
exPBNK) to target relapsed/resistant CD20+ BL cells in vitro
and in NSG mice (Chu & Cairo, ASH, 2013). Romidepsin, a
histone deacetylase inhibitor, enhances NKG2D ligands
expression (Satwani, Chu/Cairo, Cytotherapy 2014).
Objective:We investigated the combined effect of anti-CD20
CAR exPBNK cells with romidepsin against CD20+ BL in vitro
and in humanized NSG mice.
Methods: PBNK cells were expanded with inactivated K562-
mbIL15-41BBL cells and puriﬁed. Anti-CD20-4-1BB-CD3z
mRNA was nucleofected into exPBNK (Chu & Cairo, ASH,
2013). Raji, Raji-2R and Raji-4RH (provided by Matthew
Barth, MD) cells were treated with 10ng/ml romidepsin,
(Celgene Corp). MICA/B expression was analyzed by ﬂow
cytometry. NKG2D receptors were blocked using anti-NKG2D
antibodies (R & D systems). NK cytotoxicity was assessed by
europium release assays.
Romidepsin (2.2mg/kg) or PBS was i.p. injected into Raji-
Luc engrafted mice once a week for 3 weeks. 5x10*6 anti-
CD20 CAR exPBNK cells or mock exPBNK cells (without CAR
expression) were injected into each mouse 24hrs after each
romidepsin injection. Tumor regression and/or progression
was monitored by tumor volume measurements and by in
vivo bioluminescent imaging.
Results: MICA/B expression was signiﬁcantly increased in
rituximab sensitive Raji, resistant Raji-2R, and Raji-4RH cells
(P<0.001) after romidepsin treatment.
In vitro cytotoxicity of exPBNKwas signiﬁcantly enhanced
against romidepsin-treated tumor targets compared to the
untreated target cells at E:T¼3:1 (P<0.001).
Blocking NKG2D (99% to 18%) in exPBNK signiﬁcantly
reduced in vitro cytotoxicity against romidepsin treated tu-
mor targets compared to the unblocked exPBNK (P<0.001).
In vitro cytotoxicity of anti-CD20 CAR exPBNK cells was
signiﬁcantly enhanced against romidepsin-treated tumor
targets compared to the untreated at E:T¼3:1 (P<0.001), or
compared to the mock exPBNK (P<0.05) (Fig. 1A).
In humanized Raji xenograft NSG mice, the romidep-
sin+CAR exPBNK treated mice signiﬁcantly extended sur-
vival (surviving more than 100 days) compared to the
untreated (median 28 days, P<0.001), the mock exPBNK
treated mice (median 29 days, P<0.001), the CAR exPBNK
treated mice (median 42.5 days, P<0.05), the romidepsin
treated mice (median 30 days, P<0.001), and the romi-
depsin+mock exPBNK treated mice (median 34.5 days,
P<0.05) (Fig. 1B).
Conclusion: These results suggest the therapeutic potential
of the combination of anti-CD20 CAR exPBNK cells and
